Cowboy Data Corp.

For biotech companies

License your biotech data.

AI labs need real screening, tox, and regulatory data they can't find online. We review the rights and license it for you. Patient data stays out, any IP sale comes first, and you keep ownership. Nothing upfront.

What's valuable

The parts that never got published are worth the most.

Negative results

Negative results rarely reach the literature, so AI models have rarely seen them. Screening data, hits and misses alike, is scarce.

Safety signals

Tox findings, and the decisions they drove, show how real drug development works. That record rarely leaves the company.

Conversations with FDA

The back-and-forth with regulators shows how decisions actually get made. It exists only inside companies.

It takes a few hours of your time.See how it works

How it works

Four steps. A few hours of your time.

  1. Review

    We look at what data exists and who holds rights to it, including partners, licensors, and CROs.

    Your part

    One call and a list of your systems.

  2. Protect the sale

    If the program is being sold, we plan around it so licensing never reduces its value.

    Your part

    Introduce us to whoever runs the sale.

  3. Prepare the data

    We copy the data and remove personal information. Scientists document what the data means so AI labs can use it.

    Your part

    One admin login.

  4. License and get paid

    We license it to AI labs. You review samples first and earn on every license.

    Your part

    Approve samples and sign.

Get in touch

Nothing upfront. We only earn when you do.

Your situation

Three situations, three paths.

What to have ready

  1. One admin account on every system.

  2. Final data deliverables from each CRO, as they arrive.

  3. A program lead who can explain what the data means.

What we handle

Rights review, preservation, preparation, and licensing.

What drives value

Every stage leaves a record.

  1. Discovery

    Screening results, hits and misses alike.

  2. Preclinical

    Tox and safety studies, and the decisions they drove.

  3. IND

    Regulatory correspondence and the questions FDA asked.

  4. Clinical

    Regulatory and summary data. Patient-level data stays out.

Who else

Investing or buying data?

  • Investors

    For investors

    Help portfolio companies earn from data they already hold.

  • Real data from real organizations, with rights cleared.